Peptide RX

back to claim graph

proof receipt / idea

FGFR1-Selective PAM for Cartilage Anabolism

A heparin-mimetic positive allosteric modulator that potentiates endogenous FGF18-FGFR1 signaling only where ligand is already present.

grade C status published receipt fbe5033b039e proof 17%

what this node claims

FGFR1-Selective PAM for Cartilage Anabolism

A heparin-mimetic positive allosteric modulator that potentiates endogenous FGF18-FGFR1 signaling only where ligand is already present.

Open source surface

vertical proof spine

  1. 01 FGFR1-Selective PAM for Cartilage Anabolism idea / grade C / 55%
  2. 02 FGFR1 target / grade B / 70% 1 debt

evidence / risk instrument

38%
thin proof
structure evidence gates risk export lineage 38
low debt pressure 9%
28%structuredebt
pLDDT pending
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
17%lineagedebt
incomplete spine

proof completeness

17% missing fold, alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

lane
recovery
primary target
FGFR1
proof debt register

Visible limits, not hidden cleanup.

9%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

medium missing functional-site annotations link target annotation, GO term, or binding-site context

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context

what supports it

No upstream proof edge yet.

what it supports

idea names target idea:33ae8fee-a16a-4fd3-91fa-a6e3069e8aca -> target:ffdc4162-f8e6-4137-bee3-46bee6fceb6f targets / C / 0.44

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.